Danaher acquired Precision NanoSystems (PNI), which develops technologies and solutions for genetic medicines, including mRNA vaccines and therapeutics. The Vancouver, Canada-based company will join Danaher’s life sciences platform, complementing the portfolios of both Cytiva and Pall, according to Emmanuel Ligner, Danaher group executive.
“PNI has advanced a number of exciting innovations and we’re thrilled to welcome the talented team,” said Ligner. “As mRNA has matured as a successful technology in some COVID-19 vaccines, we’re seeing huge potential for this technology to accelerate other therapies. The work done so far by the PNI team will enable the customers of Cytiva and Pall to take a huge step forward in advancing their science to improve the lives of patients.”
The overall mRNA therapeutics and vaccines market is growing rapidly, associated with the development of COVID-19 mRNA vaccines. It is anticipated that mRNA technology will be used to develop other vaccines and to treat other conditions of high unmet medical need such as cancer and genetic diseases.
At present, most (35+) mRNA therapies and a large number (20+) of other types of genetic medicines in clinical development are designed to be delivered with the help of lipid nanoparticles (LNPs), noted James Taylor, co-founder and CEO of PNI.
“PNI’s Genetic Medicine Toolkit, including its GenVoyTM LNP delivery platform and NanoAssemblrTM microfluidic-based nanoparticle manufacturing platform, enables rapid development of genetic medicines,” he added.
PNI also is developing a new center of manufacturing excellence in Vancouver, which will proceed as planned, added Taylor.